Catalent to buy Cook Pharmica for $950m in cash

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Fiscal year

Cook site in Bloomington
Cook site in Bloomington
Catalent Inc has announced it will buy Cook Pharmica for $950m (€792m) in cash to boost its high tech drug production business.

The deal – which was announced today – is designed to expand Catalent’s biologics, cell culture manufacturing, and packaging capabilities.

Privately-owned Cook operates an 875,000 square foot development and manufacturing facility in Bloomington, Indiana. The firm generated revenue of $179m in the fiscal year ended June 30.

The plant houses capacity to fill 15 million vials and 70 million syringes a year.

It also provides customers with process development services as well as cell culture manufacturing. Cook also undertakes vial filling, formulation development and analytical services at the site.

Catalent CEO John Chiminski said: “We are very excited to join forces with the talented Cook Pharmica team in Bloomington, Indiana and plan to invest aggressively there, in our rapidly expanding Madison, Wisconsin facility, and in the rest of the Catalent Biologics network.”

A Catalent spokesman told us "all of Cook Pharmica’s 750 plus staff, including their executive team, will join Catalent."

Biologics

The deal is in keeping with Catalent Q3 report in May​ when it said biologics-related contracting had driven earnings growth. The contractor also predicted the proportion of revenue it generates from large molecule work will continue to increase.

At the time the firm cited deals with Roche​, Moderna Therapeutics​ and Triphase Accelerator​ as examples of its expanding biologics business.

It also reported growing interest SMARTag​ protein modification and conjugation technology.

In addition to the Madison site, Catalent Biologics’ network includes a fill-finish services facility in Brussels, Belgium and Limoges, France and the hub for its SMARTag conjugation technology in Emeryville, California.

Related topics: Upstream Processing, Bio-Outsourcing

Related news

Show more

Related products

show more

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Blazar™ Platform: Rodent Virus Panel

Blazar™ Platform: Rodent Virus Panel

Viral Safety for mAb: Prevent, Detect, Remove | 16-Nov-2020 | Technical / White Paper

We have a long history of developing innovative molecular technologies for cell line characterization and lot release testing for the biopharmaceutical...

Monitoring SARS-CoV-2 interaction with ACE2

Monitoring SARS-CoV-2 interaction with ACE2

Take the Right Path Upstream with MilliporeSigma | 02-Nov-2020 | Technical / White Paper

In this technical note, we investigate the interactions between the following: The spike glycoprotein binding with ACE2, Spike glycoprotein and anti-spike...

Related suppliers

Follow us

Products

View more

Webinars